Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid.

NCT07108036 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT07108036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07108036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid.
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
November 14, 2025
Completion date
October 31, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long covid